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The recombinant technique for the development of gene
knockout mice has played a critical role in clarifying the
biological in vivo functions of the proteins of interest. This
technique is powerful, but it requires labor-intensive and
time-consuming processes. Therefore, gene target projects
have a certain risk, especially for the young fellows who
often actually do the work. It requires multiple steps:
characterization of genomic sequences, construction of
targeted vector, screening of embryonic stem (ES) cells
with homologous recombination, injection of ES clones to
blastocysts, screening for mutant mice, etc. The real diffi-
culty, however, may start when the knockout mice do not
have any apparent phenotype.
Desmoyokin was originally identified as a new des-
mosomal plaque protein that is found at the periphery of
the cytoplasmic plaque of desmosomes in the stratified
squamous epithelia (Hieda and Tsukita, 1989). Hashimoto
and his colleagues isolated mouse monoclonal antibodies
against a desmosome preparation made from bovine muz-
zle epidermis and found that one of them recognized des-
moyokin. Using the monoclonal antibody as an antibody
probe, they immunoscreened a mouse keratinocyte ex-
pression cDNA library and isolated cDNA clones encoding
desmoyokin (Hashimoto et al, 1993). The deduced amino
acid sequence revealed that desmoyokin is identical to
AHNAK, which is a tumor-related protein of exceptionally
large size (700 kDa) and downregulated in cell lines of ne-
uroblastoma, small cell lung carcinomas, and Burkitt lymph-
omas (Shtivelman et al, 1992). AHNAK is encoded by an
intronless gene located on human chromosome 11q12–13
and has three main structural regions: the N-terminal 251
amino acids, a large central region of 4390 amino acids with
multiple repeated units of about 128 amino acids in length,
and the C-terminal of 1002 amino acids. The central region
is predicted to have antiparallel b-strands connected by
intervening loops. Several putative regulatory elements are
clustered within the C-terminal region, including nuclear
export localization signals, a leucine zipper, and potential
phosphorylation sites for protein kinase B and C (Nie et al,
2000; Sussman et al, 2001).
AHNAK/desmoyokin is a ubiquitous protein expressed in
a variety of cell types. In epithelial cells AHNAK/desmoyokin
is distributed mainly on the cell membranes, suggesting its
role in cell–cell adhesion. On the other hand, AHNAK/
desmoyokin is expressed in the nucleus and cytoplasm of non-
epithelial cells. It also shuttles between nucleus and cyto-
plasm depending on extracellular calcium concentration,
and the C-terminus is responsible for this translocation (Nie
et al, 2000). In cardiomyocytes, AHNAK/desmoyokin is as-
sociated with the regulatory b2 subunit of the cardiac L-type
Caþ2 channel through the C-terminal region (aa 5262–
5643), suggesting its role in the subsarcolemmal cytoarchi-
tecture as a linker protein between cardiac L-type Ca2þ
channels and the actin-based cytoskeleton (Hohaus et al,
2002). At the plasma membrane, AHNAK/desmoyokin in-
teracts with the annexin 2/S100A10 complex and regulates
cortical actin cytoskeleton organization and cell membrane
cytoarchitecture (Benaud et al, 2004). All of these experi-
mental results are based on the findings in vitro, using cul-
tured cells. The biological function of AHNAK/desmoyokin
in vivo remains to be elucidated.
In this issue of the JID, Kouno et al (2004) generated
AHNAK/desmoyokin-deficient mice by gene-targeting tech-
nique. The AHNAK/desmoyokin-deficient ES cells proliferat-
ed with similar doubling time to wild-type cells and showed
the normal developmental potential to differentiate into
several lineages including cardiac cells and neural cells.
AHNAK/desmoyokin-deficient mice were viable and fertile
and showed no gross developmental defects or macroscop-
ic abnormalities. Histologically, skin sections of AHNAK/des-
moyokin-deficient mice at different ages during appendage
development showed no abnormalities of hair follicles and
sebaceous glands. By immunohistochemistry, mutant epi-
dermal cells expressed the epidermal differentiation markers
laminin 5, keratin 5, keratin 1, and involucrin, as found in
normal epidermis. The mutant epidermis treated with 12-
o-tetradecanoyphorbol-13-acetate (TPA), which stimulates
protein kinase C and induces the translocation of AHNAK/
desmoyokin, showed similar increased numbers of BrdU-
incorporated cells and similar thickness of the epidermis as
found in TPA-treated normal epidermis. Electron microscop-
ic studies revealed no abnormality in the ultrastructure of
intercellular junctions or in the localization of desmocollin, a
transmembrane component of desmosomes. There was no
spontaneous tumor formation in the mutant mice, and two-
stage carcinogenesis experiments showed no significant
difference in tumor formation rates between wild-type and
the mutant mice. Taken together, the authors concluded that
the deficiency of AHNAK/desmoyokin in mice has only min-
imal, if any, effects on epidermal cell adhesion, tumorigen-
esis, cell proliferation, and differentiation.
Why no phenotype? No phenotype of mice deficient for a
certain gene indicates that other molecules compensate for
the loss of function caused by the defected gene product.
Just recently, Benaud and his colleagues used small inter-
fering RNA or siRNA, another method to see the effect by
the loss of function, and demonstrated that downregulation
of AHNAK/desmoyokin using specific siRNA prevented cor-
tical actin cytoskeleton reorganization that is required to
support cell height in Madin-Darby canine kidney cells
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